Search Within

Jonathan Eric Rosenberg

Formats
  1. Meeting Abstract (283)
  2. Journal Article (195)
  3. Review (18)
  4. Correspondence (10)
  5. Editorial (5)
  6. Guidelines (4)
  7. Book Section (2)
  8. Research Letter (2)
  9. Miscellaneous (1)
Groups
  1. Department of Medicine (520)
  2. Genitourinary Oncology Service (520)
  3. Solid Tumor Oncology Division (520)
  4. Department of Pathology and Laboratory Medicine (149)
  5. Surgery (140)
  6. Urology (137)

More Groups

People
  1. Dean Bajorin (204)
  2. Gopakumar Iyer (175)
  3. Hikmat Al-Ahmadie (134)
  4. Bernard Bochner (124)
  5. David Solit (114)
  6. Min Yuen Teo (75)

More People

Years
  1. 2025 (23)
  2. 2024 (36)
  3. 2023 (32)
  4. 2022 (36)
  5. 2021 (48)
  6. 2020 (51)

More Years

Publications
  1. Journal of Clinical Oncology (204)
  2. Annals of Oncology (42)
  3. European Urology (20)
  4. Clinical Genitourinary Cancer (18)
  5. Clinical Cancer Research (16)
  6. Cancer Research (14)

More Publications

Publishers
  1. American Society of Clinical Oncology (210)
  2. Oxford University Press (47)
  3. Elsevier Inc. (39)
  4. Elsevier Science, Inc. (36)
  5. Nature Publishing Group (36)
  6. American Association for Cancer Research (35)

More Publishers

Results (520)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Long-term outcomes in EV-301: 24-month findings from the phase 3 trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma
    Meeting Abstract

    Rosenberg, J. E.; Powles, T.; Sonpavde, G. P.; Loriot, Y.; Duran, I.; Lee, J. L.; Matsubara, N.; Vulsteke, C.; Castellano, D. E.; Mamtani, R.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Association between molecular subtype membership or hypoxia-associated gene expression signatures and clinical outcomes in the CALGB 90601 (Alliance) phase 3 clinical trial of gemcitabine and cisplatin (GC) plus bevacizumab (B) or placebo (P)
    Meeting Abstract

    McConkey, D. J.; Choi, W.; Halabi, S.; Luo, B.; Al-Ahmadie, H. A.; Rosenberg, J. E.; Mountain, J.; Regazzi, A. M.; Fong, M.; Iyer, G.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Biomarkers of response to neoadjuvant atezolizumab with gemcitabine and cisplatin in muscle-invasive bladder cancer
    Meeting Abstract

    Lattanzi, M.; Solovyov, A.; Lihm, J.; Quinlan, C.; Whiting, K.; Li, H.; Al-Ahmadie, H. A.; Teo, M. Y.; Aggen, D. H.; Ostrovnaya, I.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Association of DNA damage response (DDR) gene mutations (mts) and response to neoadjuvant cisplatin-based chemotherapy (chemo) in muscle-invasive bladder cancer (MIBC) patients (pts) enrolled onto SWOG S1314
    Meeting Abstract

    Iyer, G.; Tangen, C.; Sarfaty, M.; Regazzi, A. M.; Lee, I. L. C.; Choi, W.; Dinney, C. P. N.; Flaig, T. W.; Thompson, I. M.; McConkey, D. J.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • A phase II study of gemcitabine plus cisplatin chemotherapy in patients with muscleinvasive bladder cancer with bladder preservation for those patients whose tumors harbor deleterious DNA damage response (DDR) gene alterations (Alliance A031701)
    Meeting Abstract

    Iyer, G.; Ballman, K. V.; Atherton, P. J.; Murray, K.; Kwok, Y.; Steen, P. D.; Baghaie, S.; Rosenberg, J. E.; Morris, M. J.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Association of DNA damage repair (DDR) mutations (mts) and clinical outcomes in CALGB 90601 (Alliance)
    Meeting Abstract

    Iyer, G.; Halabi, S.; Luo, B.; Rosenberg, J. E.; Choi, W.; Al-Ahmadie, H. A.; Mountain, J.; Regazzi, A. M.; Fong, M.; Mouw, K. W.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Defining "platinum-ineligible" patients with metastatic urothelial cancer (mUC)
    Meeting Abstract

    Gupta, S.; Bellmunt, J.; Plimack, E. R.; Sonpavde, G. P.; Grivas, P.; Apolo, A. B.; Pal, S. K.; Siefker-Radtke, A. O.; Flaig, T. W.; Galsky, M. D.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • MAIN-CAV: Phase III randomized trial of maintenance cabozantinib and avelumab versus avelumab after first-line platinum-based chemotherapy in patients with metastatic urothelial cancer (mUC) (Alliance A032001)
    Meeting Abstract

    Gupta, S.; Ballman, K. V.; Galsky, M. D.; Morris, M. J.; Chen, R. C.; Chan, T. A.; Dercle, L.; Wen, Y.; Sridhar, S. S.; Yen, A. E.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • FOXA1 repression drives lineage plasticity and immune heterogeneity in bladder cancers with squamous differentiation
    Journal Article

    Warrick, J. I.; Hu, W.; Yamashita, H.; Walter, V.; Shuman, L.; Craig, J. M.; Gellert, L. L.; Castro, M. A. A.; Robertson, A. G.; Kuo, F.; more...
    Nature Communications (2022)

    Fulltext@MSK | Save
  • In reply
    Editorial

    Lacouture, M. E.; Patel, A. B.; Rosenberg, J. E.; O'Donnell, P. H.
    The Oncologist (2022)

    Fulltext@MSK | Save